New name. New look. Same commitment.
Reshaping the future of medicine.
Message from the CEO
I’m excited to announce that Moleculera Labs, Inc. has recently completed an extensive rebranding initiative that reflects our company’s expanded scope of research and product offerings. These include additional autoantibody tests in development and a unique three-part technology platform for identifying, diagnosing, and treating patients with chronic central nervous system and cardiovascular disorders driven by inflammation and immune dysfunction.
We believe in the power of precision medicine.
Our new name is Moleculera Biosciences – a move that signifies our renewed commitment to advancing precision medicine with innovative molecular testing panels, a robust biorepository of immune-mediated specimens, biomarker discovery, and novel therapeutic target identification.
As a precision medicine company, Moleculera was founded to transform how medicine is practiced by developing biomarkers to identify an immune-mediated root cause for difficult-to-treat neuropsychiatric conditions.
We are expanding into new medical sectors.
While we continue our focus on testing for autoimmune neuropsychiatric disorders, Moleculera has expanded and broadened its programs to include a pipeline of molecular autoantibody tests in development for immune-mediated cardiovascular, Long-COVID, and neurodegenerative disorders, including early-onset Alzheimer’s and Parkinson’s.
We are embarking on a new chapter with a new look.
As part of our rebranding efforts, we have changed the name of our signature panel, the Cunningham Panel™ to the Autoimmune Brain Panel™ to more accurately describe the clinical utility of molecular testing for a range of neurologic and psychiatric conditions.
We also have launched a new website – www.moleculera.com – highlighting our expansion into new medical sectors and our technology platform, including a growing biorepository and target identification programs.
We are committed to supporting providers and patients.
We are deeply grateful to the healthcare providers who have dedicated themselves to treating patients with immune-mediated neuropsychiatric disorders. And, we look forward to continuing to support providers and patients as they navigate these complex conditions.
Sincerely,
Craig Shimasaki, PhD, MBA
President & CEO, Moleculera Biosciences